Description

Hulio (adalimumab-fkjp) is a prescription biologic medication and FDA-approved biosimilar to Humira. It is a tumor necrosis factor (TNF) blocker used to treat various inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis. The medication is available as a citrate-free subcutaneous injection in both a 40 mg/0.8 mL pre-filled autoinjector pen and a pre-filled syringe format. As an interchangeable biosimilar, it offers a clinical alternative for patients managing autoimmune and chronic inflammatory disorders.

Best for

rheumatoid arthritis patients, inflammatory bowel disease management, cost-conscious biologic users, psoriasis treatment and subcutaneous injection therapy

Description

Hulio is a biosimilar medication of Adalimumab used to treat various inflammatory and autoimmune conditions including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Crohn’s Disease, Ulcerative Colitis, and Plaque Psoriasis. Classified as a Special Controlled Drug in Thailand, it is typically provided as a solution for subcutaneous injection in pre-filled syringes or auto-injector pens.

Best for

rheumatoid arthritis patients, crohn's disease treatment, specialized autoimmune care and prescribed biologic therapy

Description

Distribution and medical information services for the Adalimumab biosimilar, Hulio. While the portfolio transitioned to Biocon Biologics, Viatris remains a key historical reference and provider associated with the medication's entry into the Thailand market.

Best for

hospital pharmacy sourcing, specialty medication access and healthcare provider inquiries